FDA denies Lilly appeal

The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.